Fig. 1 · Structure

Documents & Downloads

Levosimendan

Cat. No. A11874 CAS 141505-33-1
Levosimendan is a Ca2+ sensitizer that increases contractile force of the myocardium by enhancing the sensitivity of myofilaments to calcium without increasing intracellular calcium concentration.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Cardiac troponin C

Levosimendan Research Summary

This section summarizes 1 in vivo study of Levosimendan from 1 published reference.

Levosimendan In Vivo Studies

Levosimendan was administered intraperitoneally to TauP301L-BiFC mice. Percent alternation was higher in treated mice than in the vehicle-treated group. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Levosimendan and Alternation Performance in TauP301L-BiFC Mice

Animal study · TauP301L-BiFC mice; n = 11 per group [1]

TauP301L-BiFC mice received Levosimendan intraperitoneally. Treated mice showed higher percent alternation than the vehicle-treated group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percent alternationpercent alternation 70.4 ± 4.2%[1]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
from 9 months of age for 4 months, three times a week
Vehicle
PBS containing 40% polyethylene glycol (PEG; Sigma)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Levosimendan 5 mg/kgvehicle-treated group5 mg/kg from 9 months of age for 4 months, three times a week: 70.4 ± 4.2%, p < 0.05 compared with the vehicle-treated group (52.8 ± 2.6%, p < 0.01 compared to WT).[1]
Levosimendan 5 mg/kg
Model: TauP301L-BiFC mice; n = 11 per group
Methods and source locations

Compound reported in the paper: Levosimendan

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal studies > Drug administration to TauP301L-BiFC mice (S73, S74); Results > Levosimendan rescues cognitive deficits and tau pathology in TauP301L-BiFC mice (S352, S353, S361)

percent alternation: percent alternation; comparator: vehicle-treated group — Results > Levosimendan rescues cognitive deficits and tau pathology in TauP301L-BiFC mice (S352, S353, S361)

Levosimendan 5 mg/kg · Results > Levosimendan rescues cognitive deficits and tau pathology in TauP301L-BiFC mice (S353, S361)

Specifications

Manufacturer Adooq Bioscience
CAS Number 141505-33-1
Formula C14H12N6O
Molecular Weight 280.29
SMILES
C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 48 mg/mL (171.26 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
5% DMSO+40%PEG 300+5%Tween80+50%ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Levosimendan Research References

  1. [1] Lim S, Shin S, Sung Y, et al. Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in TauP301L-BiFC mice. Exp Mol Med (2023). PMID: 36914856 DOI: 10.1038/s12276-023-00959-5 Source material

Added to your cart

View Cart Checkout
Loading...